Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY22 results · Jan–Mar 2022
Eris Lifesciences reported revenue from operations of ₹305.95 crore (up 10.0% from Q4 FY21) and net profit of ₹79.97 crore (up 17.2% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 305.95 | 278.21 | +10.0% | — | — |
| Other income | 8.06 | 2.21 | +264.4% | — | — |
| Total income | 314.01 | 280.42 | +12.0% | — | — |
| Profit before tax | 85.34 | 84.73 | +0.7% | — | — |
| Net profit for the period | 79.97 | 68.25 | +17.2% | — | — |
| Attributable to shareholders of the company | 80.30 | 68.25 | +17.7% | — | — |
| EPS, basic (₹) | 5.91 | 5.03 | +17.5% | — | — |
| Net margin (%) | 26.1 | 24.5 | — |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 282.14 | 256.85 | +9.8% | 304.63 | −7.4% |
| Other income | 9.05 | 2.75 | +229.4% | 5.84 | +55.1% |
| Total income | 291.19 | 259.60 | +12.2% | 310.47 | −6.2% |
| Profit before tax | 94.63 | 86.43 | +9.5% | 114.32 | −17.2% |
| Net profit for the period | 86.71 | 69.35 | +25.0% | 104.06 | −16.7% |
| EPS, basic (₹) | 6.38 | 5.11 | +24.9% | 7.66 | −16.7% |
| Net margin (%) | 30.7 | 27.0 | 34.2 |
Consolidated
- Filed with BSE
- 04 May 2022, 15:21 IST
- Board meeting
- 03 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 May 2022, 15:21 IST
- Board meeting
- 03 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE